Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients

Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes

“…Again, this may be because of the small number of individuals at baseline (1%) who experience partial or full blindness, resulting in imprecise estimates. This is broadly in line with findings from Hart et al, 177 who found that new cases of retinopathy result in a decrease in the EQ-5D of 0.048. Having experienced amputation results in a reduction of 0.146 in the EQ-5D in the first model with limited controls, falling to a reduction of 0.0796 in the full model.…”

“…175 found the duration of diabetes to be a significant predictor for utilities of patients with type 2 diabetes; however, this was not found for patients with type 1 diabetes in the DAFNE research database when conditioning on similar controls. A negative impact of duration of diabetes on type 1 patients was not found by Coffey et al 176 or Hart et al 177 but it was found by Ahola et al 178 in a larger sample. Having had a transplant or being on dialysis was associated with a substantial decrement in the Bagust and Beale model, 175 but not in the DAFNE data.…”

Cost-effectiveness of insulin analogues for diabetes mellitus

“…Therefore, we included only direct health care costs in the model. 12 We obtained costs for diabetes-related complications from the Ontario Diabetes Economic Model, 13 the Alberta Health Costing Project 14 and other published sources [15][16][17] ( (Table 3). 3 We assumed a cartridge-to-vial ratio of 65:35 based on utilization data from the Ontario Ministry of Health and Long-Term Care that was supplied by the Canadian Optimal Medication Prescribing and Utilization Service Advisory Committee.…”

“…3 We assumed a cartridge-to-vial ratio of 65:35 based on utilization data from the Ontario Ministry of Health and Long-Term Care that was supplied by the Canadian Optimal Medication Prescribing and Utilization Service Advisory Committee. We assumed an average patient weight of 69 kg [21][22][23] for adults with type 1 diabetes and 91 kg 14,15 for those with type 2 diabetes.…”

Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis

“…Costs associated with self-monitoring of blood glucose (SMBG) were not included as they were assumed to be similar in both treatment groups. Costs resulting from diabetes complications management (i.e., use of concomitant medications) and treatment, as well as from insulin adverse events treatment, were derived from the published literature, mainly from sources used in the 2008 COMPUS report [32][33][34][35][36][37][38][39][40][41][42][43][44] ; diabetes complication and insulin adverse events treatment costs were adjusted to 2010 Canadian dollars using the health component of the Consumer Price Index (Table 4) 45 .…”